ANAB AnaptysBio, Inc.

11.880.69 (+6.17%)
Close: November 21, 2019

11.86-0.02 (-0.17%)
After hours

Quote

Previous Close
$11.88
Day Range
$11.05-$11.92
52 Week Range
$10.00-$83.10
Volume
726,137
Avg Volume
1,272,902
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$322.35M
Enterprise Value (EV)
-$115.26M
PE Ratio
-
EV/EBITDA
1.73
Price/Sales
-
Price/Book
0.66
PEG Ratio
0.05

Financials

Revenue
-
Gross Profit
-
EBITDA
-$66.51M
EPS, ttm
-$3.49
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
3/9/2020 (108 days)
Debt to Equity
2%
Debt
-
Cash
$427.08M
Net Debt
-

Performance

Beta
1.34
200 Day Moving Avg
$55.94
50 Day Moving Avg
$32.71
52 Week Change
-84.67%
YTD Change
-76.27%
1 Month Change
-69.53%
3 Month Change
-74.15%
6 Month Change
-84.16%
1 Year Change
-84.67%
2 Year Change
-85.13%
5 Year Change
-25.40%

Share Count

Shares Outstanding
27.1M
Float
24.5M
Restricted Shares
2.7M
Restricted Shares, %
9.83%

AnaptysBio, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Hamza Suria

Website: http://www.anaptysbio.com

Description: AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Employees: 78